Chang J Y, Dethlefsen L A, Barley L R, Zhou B S, Cheng Y C
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510.
Biochem Pharmacol. 1992 Jun 9;43(11):2443-52. doi: 10.1016/0006-2952(92)90325-d.
Three camptothecin-resistant sublines (V79r, IRS-1r and IRS-2r) of V79 cells and their irradiation-sensitive mutants, IRS-1 and IRS-2, were developed by stepwise, continuous exposure to camptothecin (CPT). The degree of resistance varied among these cells. Based on the biochemical characterizations of these resistant cell lines, the mechanisms which could be responsible for the resistance to CPT were proposed to be: (a) a decrease in the intracellular accumulation of CPT with or without alteration of DNA topoisomerase I, (b) a decrease in the amount of DNA topoisomerase I, or (c) a decrease in the sensitivity of DNA topoisomerase I to CPT. The resistant cells which exhibited down-regulation of DNA topoisomerase I were collaterally sensitive to etoposide (VP-16) and its analogue, 4'-demethy-4 beta-(4"-fluoroanilino)-4-desoxypodophyllotoxin, despite the fact that there were equal amounts of DNA topoisomerase II in the parental and in the resistant cell lines. Alternating the usage of CPT and VP-16 for the treatment of cancer is indicated.
通过逐步连续暴露于喜树碱(CPT),培育出了V79细胞的三个耐喜树碱亚系(V79r、IRS-1r和IRS-2r)及其辐射敏感突变体IRS-1和IRS-2。这些细胞的耐药程度各不相同。基于这些耐药细胞系的生化特性,推测导致对CPT耐药的机制可能为:(a)CPT在细胞内的积累减少,无论DNA拓扑异构酶I是否发生改变;(b)DNA拓扑异构酶I的量减少;或(c)DNA拓扑异构酶I对CPT的敏感性降低。尽管亲代细胞系和耐药细胞系中的DNA拓扑异构酶II含量相等,但表现出DNA拓扑异构酶I下调的耐药细胞对依托泊苷(VP-16)及其类似物4'-去甲基-4β-(4''-氟苯胺基)-4-脱氧鬼臼毒素具有侧链敏感性。建议交替使用CPT和VP-16治疗癌症。